The patient's appraisal of side-effects: the blind spot in quality-of-life assessments in transplant recipients.
and mortality in end-stage renal disease. Kidney Int 1996; 49: dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Nephrol Dial Transplant 1998; 13: 1379–1385 9. Lowrie EG, Lew NL. Death risk in haemodialysis patients: the 3030–3033 14. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Jacobsen DW, Robinson K, Dennis VW. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor Dis 1990; 15: 458–482 10. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensec B, in end-stage renal disease. Circulation 1998; 97: 138–141 15. Hornberger J, Wrone E. When to base clinical policies on Dieplinger H, Kronenberg F. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein (a) phenotypes predict observational versus randomized trial data. Ann Intern Med 1997; 127: 697–703 coronary artery disease in haemodialysis patients. J Am Soc Nephrol 1997; 8: 1889–1898 16. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium×phosphate prod11. Ma JZ, Ebben J, Xia H, Collins AJ. Haematocrit level and associated mortality in haemodialysis patients. J Am Soc Nephrol uct with mortality risk in chronic haemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–617 1999; 10: 610–619 12. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, 17. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low haematocrit values in patients with cardiac haemodialysis patients. Kidney Int 1999; 55: 648–658 18. Zoccali C, on behalf of the CREED Investigators. C Reactive disease who are receiving haemodialysis and epoetin. N Engl J Med 1998; 339: 584–590 protein and atherosclerosis in dialysis patients. Nephrol Dial Transplant 1998; 13: 2710–2711 13. Macdougall IC, Ritz E. The Normal Haematocrit Trial in